Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announce a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio and aligns with its long-standing commitment to bringing transformational medicines to patients.
Read the full article: Gilead Sciences Expands Liver Portfolio with Acquisition of CymaBay Therapeutics //
Source: https://www.businesswire.com/news/home/20240211034242/en/Gilead-Sciences-Expands-Liver-Portfolio-With-Acquisition-of-CymaBay-Therapeutics